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Summary
Background: Understanding the true prevalence of
lymphangioleiomyomatosis (LAM) is important in
estimating disease burden and targeting specific
interventions. As with all rare diseases, obtaining
reliable epidemiological data is difficult and requires
innovative approaches.
Aim: To determine the prevalence and incidence of
LAM using data from patient organizations in seven
countries, and to use the extent to which the preva-
lence of LAM varies regionally and nationally to de-
termine whether prevalence estimates are related to
health-care provision.
Methods: Numbers of women with LAM were
obtained from patient groups and national data-
bases from seven countries (n = 1001). Prevalence
was calculated for regions within countries using
female population figures from census data.
Incidence estimates were calculated for the USA,
UK and Switzerland. Regional variation in preva-
lence and changes in incidence over time were
analysed using Poisson regression and linear
regression.
Results: Prevalence of LAM in the seven countries
ranged from 3.4 to 7.8/million women with signifi-
cant variation, both between countries and between
states in the USA. This variation did not relate to the
number of pulmonary specialists in the region nor
the percentage of population with health insurance,
but suggests a large number of patients remain un-
diagnosed. The incidence of LAM from 2004 to
2008 ranged from 0.23 to 0.31/million women/per
year in the USA, UK and Switzerland.
! The Author 2011. Published by Oxford University Press on behalf of the Association of Physicians.
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Conclusions: Using this method, we have found that
the prevalence of LAM is higher than that previously
recorded and that many patients with LAM are
undiagnosed.
Introduction
Lymphangioleiomyomatosis (LAM) is a rare disease,
which predominantly affects the lungs, kidneys and
lymphatics. Patients are almost exclusively women
and the age of onset is generally between the me-
narche and the menopause.1–3 Dyspnoea and
pneumothorax result from cystic destruction of the
lungs due to the growth of immature smooth
muscle-like cells (LAM cells), which infiltrate the
lung parenchyma.1,4 LAM is generally progressive
and can lead to respiratory failure.5 The disease
can occur sporadically or as part of tuberous scler-
osis complex (TSC)6 with both forms of LAM being
associated with mutations in TSC1 or more com-
monly TSC2, the genes known to cause TSC.7,8
The prevalence of LAM was estimated at 2.6 cases/
million women aged 20–69 years in France in 19979
and as 1/1.1 million of the total population of the UK
in 2000.10 After these studies, several factors, and
particularly the increased use of high-resolution
computerised tomography (CT) scanning, have con-
tributed to increasing awareness of LAM and earlier
diagnosis.11–13
Obtaining prevalence data on rare diseases is dif-
ficult, but important for a better understanding of the
natural history of the disease. LAM is not specifically
named in the WHO International Classification of
Disease 10 (ICD-10), making it difficult to estimate
prevalence and incidence for epidemiological ana-
lyses. The awareness of rare diseases, such as LAM,
among physicians has increased through patient
groups that raise awareness and provide support
specifically for patients with LAM and organizations
that promote rare diseases (e.g. Orphanet).14 The
established groups are easily accessible to patients
and keep records on their members.
Anecdotal evidence from patient groups and spe-
cialist centres suggest that the prevalence of LAM
may be greater than previously reported, and rates
of diagnosis may vary between countries. In this study,
we used data from patient groups in the USA, UK,
Canada, Australia, New Zealand, Switzerland and
Germany to examine the current prevalence and in-
cidence of LAM.
Methods
Countries were included in the study, if they had
LAM organizations with a database of patients,
were not restricted to one region of the country
and had been established for at least 5 years.
Registries and patient groups provided anonymous
data on date of birth and date and region of diagno-
sis for all living patients with physician diagnosed
LAM. No distinction was made between sporadic
and TSC-associated LAM.
Patient identification
The number of patients with LAM and their county,
state, region or canton at the time of diagnosis was
obtained from LAM Action and the national LAM
register (UK), the LAM Foundation (USA), LAM
Canada, The New Zealand LAM Charitable Trust,
LAM Selbsthilfe (Germany) and LAM Australasia
Research Alliance. Swiss data were obtained from
the Swiss Registries for Interstitial and Orphan Lung
Diseases (SIOLD), a recruitment tool for research on
rare pulmonary disorders. Data on patients diag-
nosed in one canton was unobtainable and preva-
lence figures were adjusted to account for this. Data
on ethnic origin and lung transplantation was also
available from the UK LAM register. The UK, USA
and Swiss registries also provided data on incident
cases. The UK LAM register is approved by the UK
multicentre research ethics committee and patients
sign informed consent. For patients outside the UK,
ethical permissions were not required as only pa-
tient numbers were used.
Population and health services data
The female population for each state or canton in
the USA, Germany and Switzerland was acquired
from the 2008 census,15–17 for Canadian provinces
from the 2007 census,18 for New Zealand districts
and territory in Australia from the 2006 census19,20
and for counties in the UK, including ethnic distri-
bution, from the 2001 census.21
The number of pulmonary doctors in each US
state was acquired from the American Board of
Internal Medicine and the number of respiratory
consultants in each UK county from the 2008
British Thoracic Society directory of Training Posts
and Services in Adult Respiratory Medicine.
Academic respiratory centres in the UK were
defined as University hospitals with at least one pro-
fessor and five consultants in respiratory medicine.
The health insurance coverage of each state of the
USA was obtained from the 2008 census.22 The Gini
index, a measure of the inequality in distribution
of household income within a country, was
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obtained from The World Factbook from the Central
Intelligence Agency, USA.23 The higher the Gini
index of a country, the more unequal its income
distribution. Most countries have a Gini index
lying between 25 and 50.
Analysis
The prevalence of patients with LAM per million
female population was estimated for each country
and region. The incidence (number of new LAM
cases diagnosed per million female population per
year) was calculated over the 5-year period from
2004 to 2008. A crude estimate of median survival
for patients with LAM from the date of diagnosis was
estimated by dividing the prevalence by the mean
yearly incidence over this period.
To examine if significant variation in the preva-
lence of diagnosed LAM exists between regions or
countries, Poisson regression was performed on
prevalence data and a likelihood ratio test carried
out. Associations between prevalence of diagnosed
LAM and numbers of pulmonary physicians per mil-
lion women (USA and UK), academic centres (UK),
wealth distribution (between countries) or health in-
surance coverage (USA only) were tested by Poisson
regression.
An estimate for the number of potentially undiag-
nosed cases of LAM was obtained from the observed
variations in prevalence, by assuming that the lower
prevalence in some countries or regions compared
with other countries or regions is explained by geo-
graphical variation in confirming a diagnosis. Using
a conservative estimate that the true prevalence of
LAM lies between the median and maximum values
for the countries studied, we estimated a possible
true prevalence range by applying the mean and
maximum prevalence figures for all seven countries
to individual countries.
All analyses were conducted using STATA version
10.1 (StataCorp LP, Texas, USA).
Results
A total of 1001 patients with physician diagnosed
LAM were identified in the seven countries. Of
them, 17 were withdrawn as the original diagnosis
was made in a country not included in the study,
leaving 984 patients for analysis. From the UK
where extra data were available, 88% of patients
were of white UK origin and the remainder of
other European, Asian and Chinese origin. This
ethnic distribution did not differ from that of the
UK population as a whole. Of them, 17 (9%) pa-
tients in the UK had undergone lung transplantation.
Prevalence
The median prevalence of diagnosed LAM for all
countries was 4.9 cases/million female population
(range 3.35–7.76). The differences in prevalence be-
tween countries were significant (P < 0.01, Table 1).
The prevalence of LAM also varied between re-
gions within countries and these regional differences
were significant in the USA and Canada (Table 1
and Supplementary Figures E1–E4). We examined
the reasons for this variation within the USA and
UK, where 523 and 148 women, respectively, had
been diagnosed with LAM. Prevalence across all
52 US states ranged from 0.0 to 9.13 cases/million
female population (mean 3.35, median 3.15, Figure 1
and Table 2). Prevalence across UK counties
ranged from 0.0 to 15.5 cases/million female popu-
lation (mean 4.9, median 4.6). Although the over-
all variation in the UK was not significant, there
were differences between the highest and lowest
values (P < 0.001, Figure 2 and Supplementary
Table E1).
We tested to see if the differences observed
related to regional differences in access to pulmon-
ary specialists or health insurance. There was no
relationship between the prevalence of LAM with
the number of pulmonary doctors nor the proportion
of patients with health insurance in individual states
(Supplementary Figure E5). Similarly, the number of
respiratory consultants was not related to the preva-
lence of LAM in counties of the UK (Supplementary
Figure E6). Twenty seven centres in the UK fitted our
criteria for academic respiratory centres. The pres-
ence of an academic respiratory centre was not
associated with the prevalence of LAM across indi-
vidual counties (P = 0.57). The prevalence of LAM
was not related to the Gini coefficient for the seven
countries (P = 0.93, Supplementary Figure E7). There
was a trend towards countries with smaller popula-
tions having higher prevalence rates, but this was
not significant (Supplementary Figure E8, R2 = 0.43,
P = 0.11).
Incidence
The mean standard deviation (SD) incidence of LAM
per million female population between 2004 and
2008 was 0.31 (0.058) cases/year in the USA, 0.23
(0.076) in the UK and 0.37 (0.26) in Switzerland.
The incidence did not vary significantly from
year-to-year over this period (Figure 3, P = 0.89).
Combining our data on the prevalence and inci-
dence of LAM, a crude estimate of the median sur-
vival from diagnosis was 12 years across all
countries.
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Estimates of true prevalence of LAM
The median and maximum values of prevalence for
the countries we studied were 4.89 and 7.76 pa-
tients/million women. Applying these values to the
year 2000 world female population of 3 billion’ to
make clearer. We estimate that they are between
15 000 and 23 000 patients with LAM worldwide.
We applied the same method to the USA, the coun-
try with the lowest prevalence and largest popula-
tion studied. This predicts that there may be
between 764 and 1212 patients in the USA; suggest-
ing that 241–689 patients are undiagnosed. These
estimates for other countries are provided in
Supplementary Table E2.
Discussion
Using details obtained predominantly from patient
organizations, we found a prevalence of LAM be-
tween 3.35 and 7.76 cases/million women in seven
countries. This is higher than previous estimates of
2.6 cases/million women aged 20–69 years in
France9 and 1/1.1 million of the total population
in the UK.10 These studies, published in 1997 and
2000, respectively, were smaller and relied on data
from respiratory physicians only. It is possible that
the prevalence of LAM has increased since 2000 but
much more likely that this rise is due to better iden-
tification of patients and supports our contention
that patient organizations can provide useful data
to study rare diseases.
Regional variation in prevalence of LAM
Variation in prevalence was observed between the
seven countries and between states of the USA and
Canada. It is possible that the true prevalence of
LAM varies between separate regions or countries,
although the magnitude of the differences between
adjacent, geographically and culturally similar re-
gions suggest that variation in diagnostic
Figure 1. Prevalence of LAM across the USA. Prevalence across states ranged between 0.00 and 9.13 cases/million female
population (median 3.15). This regional variation is significant (P = 0.012).
Table 1 Prevalence of LAM in seven countries
Country Female
population
LAM
patients
Prevalence Maximum
regional
prevalence
P-value*
USA 156 191 761 523 3.35 9.13 0.012
Germany 41 818 073 155 3.77 14.70 0.17
Canada 16 643 900 69 4.15 64.91 0.0041
UK 30 280 000 148 4.89 15.47 0.20
Australia 10 056 041 52 5.17 18.25 0.56
Switzerland 3 240 073 21 6.48 20.42 0.27
New Zealand 2 062 053 16 7.76 20.19 0.27
Prevalence figures are patients per million women of the population.
*P-values are for comparison between regions within a single country.
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Table 2 USA regional prevalence data
State Female population LAM patients Prevalence IRR (95% confidence interval)]
Delaware 449 756 0 0
New Mexico 1 006 030 0 0
North Dakota 319 548 0 0
Puerto Rico 2 056 641 1 0.49 2.89 (0.85–9.86)
Oklahoma 1 843 520 1 0.54 2.00 (0.73–5.49)
West Virginia 925 772 1 1.08 3.93 (1.31–11.75)
Alabama 2 403 813 4 1.66 1.68 (0.45–6.24)
Rhode Island 542 083 1 1.84 0.00 (0.00)
Tennessee 3 185 773 6 1.88 1.93 (0.22–17.24)
Mississippi 1 514 777 3 1.98 1.68 (0.58–4.80)
Montana 482 955 1 2.07 1.47 (0.47–4.54)
North Carolina 4 705 427 10 2.13 1.88 (0.34–10.27)
Louisiana 2 269 998 5 2.20 2.38 (0.53–10.64)
Utah 1 355 163 3 2.21 2.66 (0.94–7.58)
Texas 12 183 416 28 2.30 2.60 (0.86–7.90)
Nevada 1 275 577 3 2.35 1.98 (0.53–7.36)
Georgia 4 920 769 12 2.44 1.70 (0.43–6.82)
South Dakota 403 333 1 2.48 1.65 (0.47–5.86)
South Carolina 2 298 522 6 2.61 1.32 (0.36–4.93)
Kentucky 2 181 103 6 2.75 1.78 (0.33–9.73)
Connecticut 1 793 842 5 2.79 2.07 (0.65–6.59)
Florida 9 323 058 26 2.79 2.87 (0.96–8.60)
Kansas 1 410 313 4 2.84 2.60 (0.90–7.55)
Maine 674 087 2 2.97 2.75 (0.89–8.53)
New Hampshire 666 722 2 3.00 1.19 (0.27–5.32)
Hawaii 638 679 2 3.13 2.39 (0.77–7.39)
Vermont 315 547 1 3.17 1.24 (0.14–11.13)
District of Columbia 311 953 1 3.21 2.01 (0.45–8.96)
Iowa 1 519 683 5 3.29 1.41 (0.32–6.32)
California 18 368 644 61 3.32 reference
Nebraska 899 152 3 3.34 2.31 (0.78–6.85)
Maryland 2 906 274 10 3.44 0.00 (0.00)
Ohio 5 882 142 21 3.57 2.28 (0.81–6.38)
Pennsylvania 6 388 109 23 3.60 1.28 (0.40–4.07)
New York 10 028 234 38 3.79 0.00 (0.00)
New Jersey 4 430 879 17 3.84 2.15 (0.74–6.25)
Idaho 757 236 3 3.96 0.33 (0.04–2.92)
Missouri 3 023 698 12 3.97 2.84 (0.87–9.21)
Arizona 3 243 489 13 4.01 2.16 (0.75–6.26)
Wisconsin 2 830 318 12 4.24 0.29 (0.03–2.61)
Indiana 3 234 282 14 4.33 1.11 (0.12–9.92)
Michigan 5 079 493 22 4.33 1.57 (0.44–5.56)
Illinois 6 541 657 29 4.43 1.49 (0.17–13.33)
Minnesota 2 620 494 12 4.58 1.13 (0.32–4.01)
Oregon 1 907 329 9 4.72 1.38 (0.48–3.94)
Massachusetts 3 344 791 16 4.78 1.33 (0.30–5.94)
Arkansas 1 456 755 7 4.81 1.90 (0.21–17.04)
Virginia 3 952 047 21 5.31 3.19 (1.10–9.30)
Washington 3 279 299 19 5.79 3.48 (1.18–10.23)
Colorado 2 448 415 16 6.53 0.65 (0.07–5.81)
Wyoming 262 478 2 7.62 2.55 (0.82–7.90)
Alaska 328 686 3 9.13 4.58 (0.84–25.00)
There are 523 living patients with LAM in the USA (female population of 156 million.) The overall prevalence of LAM across
the USA is 3.35 cases/million women. Variation between states is statistically significant (P = 0.012). IRR, incidence-rate ratio
for LAM. Prevalence figures are patients per million women of the population.
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ascertainment is more likely to occur. Surprisingly,
no association was observed between the preva-
lence of LAM and the number of pulmonary special-
ists, academic respiratory centres, nor with access to
health insurance. The observed regional variation
may still be attributable to factors related to recog-
nition of LAM as we were unable to test whether
prevalence figures were higher in regions with
physicians with particular expertise in LAM as this
is not possible to identify in all cases.
Incidence of LAM
Although the prevalence of LAM is higher in our
study than that previously recorded, the incidence
had not increased over 5 years. There have been no
Figure 2. Prevalence of LAM across the UK. Prevalence across counties ranged between 0.00 and 15.47 cases/million
female population (median 4.6). This regional variation is not significant (P = 0.20).
Figure 3. Incidence of LAM from 2004 to 2008 in three countries. The incidence of LAM between 2004 and 2008 per
million female population per year. The incidence did not change significantly over time (P = 0.89).
976 E.C. Harknett et al.
major developments in the methods used to diag-
nose LAM over the last 5 years and it is likely that
any increase in incidence due to increased recogni-
tion occurred prior to this when the availability of
CT scanning was increasing. Early diagnosis of pa-
tients will result in an increased prevalence of LAM
and would explain the rise in prevalence with no
overall rise in incidence.
The only previous estimate of the incidence of
LAM was 0.23 patients/million females/year in
France between 1991 and 1996 (reported as
0.4 cases/million women aged 20–69 years/year).9
The mean incidence between 2004 and 2008 in our
study, 0.3/million women/year, is similar despite the
differences in data collection methods between the
two studies.
It is now recognized that a number of patients
with LAM live for over 20 years from the onset of
symptoms.24,25 Estimates of survival performed be-
tween 1990 and 2004 range from 71% to 91% at 10
years from symptom onset.5,24 These figures may
have improved due to earlier diagnosis and the
increasing use of lung transplantation over this
period. The true median survival is difficult to esti-
mate as this would require a large, representative
cohort of incident cases followed-up for at least 20
years. The value obtained by our method is less than
clinical experience and observational studies would
suggest. The approach we used to calculate me-
dian survival is less prone to survivor bias than
other studies, but is very reliant on the number
of cases identified. The low estimate here is likely
to be a consequence of a greater number of unrec-
ognised cases of LAM in areas reporting low
prevalence.
Predicted number of missing cases
We estimated that in the USA alone, there may be as
many as 689 patients living with LAM with no de-
tails registered with the LAM Foundation. These pa-
tients have either been diagnosed with LAM, but
chose not to register with the patient group, or
have not yet been diagnosed with LAM. As the
LAM Foundation is the longest established and high-
est profile patient group for LAM worldwide, it is
unlikely that they only have details on 40% of pa-
tients in the US living with LAM. We predict, there-
fore, that a significant number of patients with
symptomatic LAM remain undiagnosed. Making a
correct diagnosis would have potential benefits for
these patients. Simple interventions that can benefit
patients with LAM include avoidance of oestrogens,
careful consideration of pregnancy and early surgi-
cal treatment of pneumothorax.26
Our study has a number of limitations. Obtaining
accurate data on patients with rare diseases is diffi-
cult and differences in data ascertainment may have
biased our findings. As patients self-register with
these organizations, individual diagnoses are neither
independently verified nor are patient deaths always
recorded. However, these potential errors are likely
to represent only a small portion of cases and are not
likely to differ significantly between groups. We
have attempted to minimize these sources of vari-
ation by selecting similar patient groups with respect
to how well-established they are in their country and
that they were well recognized by physicians and
patients alike. We are aware that not all patients
diagnosed with LAM will have registered with their
national patient group, but this is also likely to be
true of other registry techniques. This is particularly
likely to apply to patients with TSC. The prevalence
of TSC is not thought to vary significantly between
regions including Europe and the USA with a re-
ported prevalence of 8.8 and 10.6/100 000, respect-
ively.27,28 About 40% of the women with TSC have
LAM when studied by chest CT and it is possible that
these patients have not been screened, or if diag-
nosed, continue to associate with TSC groups
rather than LAM organizations.
Conclusions
We have used incidence and prevalence data from
patient groups for the first time to study 984 patients,
and provide a clearer picture of the epidemiology of
LAM. The estimated prevalence of LAM in seven
countries was between 3.35 and 7.76 cases/million
women with an incidence of 0.23–0.31/million
women/year. Combining data sets is an important
way forward for rare diseases where numbers of pa-
tients in individual countries are small. Further re-
search to explain the variation in prevalence of LAM
requires comprehensive research networks, and
could eventually improve recognition and hence
management of this rare disease.
Supplementary Data
Supplementary Data are available at QJMED
Online.
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